Entero Therapeutics, Inc.
ENTO
$1.94
$0.042.11%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -80.41% | -90.57% | -54.03% | -30.41% | 13.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -81.35% | -90.97% | -70.60% | -44.87% | -18.07% |
| Operating Income | 81.35% | 90.97% | 70.60% | 44.87% | 18.07% |
| Income Before Tax | 80.32% | 89.58% | 70.88% | 44.81% | 18.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 91.22% | -116.46% | -187.71% | 44.81% | -83.46% |
| Earnings from Discontinued Operations | 71.19% | -61.57% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.67% | -122.62% | -198.43% | 24.84% | -110.25% |
| EBIT | 81.35% | 90.97% | 70.60% | 44.87% | 18.07% |
| EBITDA | 81.27% | 91.00% | 69.71% | 44.79% | 18.77% |
| EPS Basic | 94.12% | -109.01% | 39.57% | 93.64% | 89.78% |
| Normalized Basic EPS | 90.53% | 96.59% | 109.14% | 95.41% | 95.95% |
| EPS Diluted | 94.12% | -189.03% | 39.57% | 93.64% | 89.78% |
| Normalized Diluted EPS | 90.53% | 71.91% | 109.14% | 95.41% | 95.95% |
| Average Basic Shares Outstanding | 107.70% | 170.44% | 339.88% | 1,103.25% | 1,923.02% |
| Average Diluted Shares Outstanding | 107.70% | -67.16% | 339.88% | 1,103.25% | 1,923.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |